Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation

British Journal of Haematology

Volumn 138, Issue 3, 2007, Pages 354-358

  Gangat, Naseema ^a   Strand, Jacob ^a   Li, Chin Yang ^a   Wu, Wenting ^a   Pardanani, Animesh ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

JAK2; Leukaemia; Prognosis; Survival; Thrombosis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; LYMPHOCYTE TRANSFORMATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POLYCYTHEMIA VERA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STATISTICAL ANALYSIS; SURVIVAL RATE; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; FIBROSIS; HUMANS; LEUKEMIA; LEUKOCYTOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYCYTHEMIA VERA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL RATE; THROMBOSIS;

EID: 34447132275     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06674.x     Document Type: Article

References (33)

1. Antonioli, E., Guglielmelli, P., Pancrazzi, A., Bogani, C., Verrucci, M., Ponziani, V., Longo, G., Bosi, A. Vannucchi, A.M. (2005) Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia, 19, 1847 1849.
2. Barbui, T. Finazzi, G. (2006) Evidence-based management of polycythemia vera. Best Practice and Research in Clinical Haematology, 19, 483 493.
3. Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. Green, A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054 1061.
4. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. Sultan, C. (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. British Journal of Haematology, 33, 451 458.
5. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. Sultan, C. (1991) Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). British Journal of Haematology, 78, 325 329.
6. Berk, P.D., Goldberg, J.D., Donovan, P.B., Fruchtman, S.M., Berlin, N.I. Wasserman, L.R. (1986) Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Seminars in Hematology, 23, 132 143.
7. Campbell, P.J., Scott, L.M., Buck, G., Wheatley, K., East, C.L., Marsden, J.T., Duffy, A., Boyd, E.M., Bench, A.J., Scott, M.A., Vassiliou, G.S., Milligan, D.W., Smith, S.R., Erber, W.N., Bareford, D., Wilkins, B.S., Reilly, J.T., Harrison, C.N. Green, A.R. (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet, 366, 1945 1953.
8. Campbell, P.J., Griesshammer, M., Dohner, K., Dohner, H., Kusec, R., Hasselbalch, H.C., Larsen, T.S., Pallisgaard, N., Giraudier, S., Le Bousse-Kerdiles, M.C., Desterke, C., Guerton, B., Dupriez, B., Bordessoule, D., Fenaux, P., Kiladjian, J.J., Viallard, J.F., Briere, J., Harrison, C.N., Green, A.R. Reilly, J.T. (2006) V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood, 107, 2098 2100.
9. Carobbio, A., Finazzi, G., Guerini, V., Spinelli, O., Delaini, F., Marchioli, R., Borrelli, G., Rambaldi, A. Barbui, T. (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood, 109, 2310 2313.
10. Cheung, B., Radia, D., Pantelidis, P., Yadegarfar, G. Harrison, C. (2006) The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. British Journal of Haematology, 132, 244 245.
11. Di Nisio, M., Barbui, T., Di Gennaro, L., Borrelli, G., Finazzi, G., Landolfi, R., Leone, G., Marfisi, R., Porreca, E., Ruggeri, M., Rutjes, A.W., Tognoni, G., Vannucchi, A.M. Marchioli, R. (2007) The haematocrit and platelet target in polycythemia vera. British Journal of Haematology, 136, 249 259.
12. Dingli, D., Schwager, S.M., Mesa, R.A., Li, C.Y. Tefferi, A. (2006) Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia. Cancer, 106, 623 630.
13. Dupriez, B., Morel, P., Demory, J.L., Lai, J.L., Simon, M., Plantier, I. Bauters, F. (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood, 88, 1013 1018.
14. Finazzi, G., Caruso, V., Marchioli, R., Capnist, G., Chisesi, T., Finelli, C., Gugliotta, L., Landolfi, R., Kutti, J., Gisslinger, H., Marilus, R., Patrono, C., Pogliani, E.M., Randi, M.L., Villegas, A., Tognoni, G. Barbui, T. (2005) Acute leukemia in polycythemia vera. An analysis of 1,638 patients enrolled in a prospective observational study. Blood, 105, 2664 2670.
15. Gangat, N., Wolanskyj, A.P., Schwager, S.M., Mesa, R.A. Tefferi, A. (2006) Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia. Cancer, 106, 2406 2411.
16. Gangat, N., Wolanskyj, A.P., McClure, R.F., Li, C.Y., Schwager, S., Wu, W. Tefferi, A. (2007) Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia, 21, 270 276.
17. Heller, P.G., Lev, P.R., Salim, J.P., Kornblihtt, L.I., Goette, N.P., Chazarreta, C.D., Glembotsky, A.C., Vassallu, P.S., Marta, R.F. Molinas, F.C. (2006) JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. European Journal of Haematology, 77, 210 216.
18. James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144 1148.
19. Kiladjian, J.J., Gardin, C., Renoux, M., Bruno, F. Bernard, J.F. (2003) Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. Hematology Journal, 4, 198 207.
20. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine, 352, 1779 1790.
21. Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C. Barbui, T. (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. New England Journal of Medicine, 350, 114 124.
22. Landolfi, R., Di Gennaro, L., Barbui, T., De Stefano, V., Finazzi, G., Marfisi, R., Tognoni, G. Marchioli, R. (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood, 109, 2446 2452.
23. Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D'Andrea, A., Frohling, S., Dohner, K., Marynen, P., Vandenberghe, P., Mesa, R.A., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.R., Lee, S.J. Gilliland, D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387 397.
24. Passamonti, F., Rumi, E., Pungolino, E., Malabarba, L., Bertazzoni, P., Valentini, M., Orlandi, E., Arcaini, L., Brusamolino, E., Pascutto, C., Cazzola, M., Morra, E. Lazzarino, M. (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. American Journal of Medicine, 117, 755 761.
25. Pemmaraju, N., Moliterno, A.R., Williams, D., Rogers, O. Spivak, J.L. (2006) Heterogeneous JAK2V617F allele burden in essential thrombocytosis. Gender and clinical correlates. Blood, 108, Abstract # 670.
26. Scott, L.M., Tong, W., Levine, R.L., Scott, M.A., Beer, P.A., Stratton, M.R., Futreal, P.A., Erber, W.N., McMullin, M.F., Harrison, C.N., Warren, A.J., Gilliland, D.G., Lodish, H.F. Green, A.R. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. New England Journal of Medicine, 356, 459 468.
27. Tefferi, A., Lasho, T.L., Schwager, S.M., Strand, J.S., Elliott, M., Mesa, R., Li, C.Y., Wadleigh, M., Lee, S.J. Gilliland, D.G. (2006) The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer, 106, 631 635.
28. Tefferi, A., Gangat, N. Wolanskyj, A. (2007) The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia. Blood, 109, 4105.
29. Thiele, J., Vardiman, J.W., Pierre, R., Brunning, R.D., Imbert, M. Flandrin, G. (2001) Chronic idiopathic myelofibrosis. In : World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues (ed. by E.S. Jaffe, N.L. Harris, H. Stein J.W. Vardiman pp. 35 38. International Agency for Research on Cancer (IARC) Press, Lyon, France.
30. Vannucchi, A.M., Antonioli, E., Guglielmelli, P., Pancrazzi, A., Bogani, C., Pieri, L. Bosi, A. (2006) Influence of the Jak2V617F mutational load at diagnosis on major clinical aspects in patients with polycythemia vera. Blood, 108, Abstract # 5.
31. Vardiman, J.W., Brunning, R.D. Harris, N.L. (2001) WHO histological classification of chronic myeloproliferative diseases. In : World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues (ed. by E.S. Jaffe, N.L. Harris, H. Stein J.W. Vardiman pp. 17 44. International Agency for Research on Cancer (IARC) Press, Lyon, France.
32. Wolanskyj, A.P., Lasho, T.L., Schwager, S.M., McClure, R.F., Wadleigh, M., Lee, S.J., Gary Gilliland, D. Tefferi, A. (2005) JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. British Journal of Haematology, 131, 208 213.
33. Wolanskyj, A.P., Schwager, S.M., McClure, R.F., Larson, D.R. Tefferi, A. (2006) Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clinic Proceedings, 81, 159 166.